Efficacy of long-acting insulin analog insulin glargine at high dosage for basal-bolus insulin therapy in patients with type 2 diabetes

Tokai Journal of Experimental and Clinical Medicine

Volumn 37, Issue 2, 2012, Pages 35-40

  Suzuki, Daisuke ^a   Toyoda, Masao ^a   Kondo, Masumi ^a   Miyatake, Han ^a   Tanaka, Eitaro ^a   Sato, Hiroki ^a   Kuriyama, Yusuke ^a   Miyauchi, Masaaki ^a   Yamamoto, Naoyuki ^a   Kimura, Moritsugu ^a   Umezono, Tomoya ^a   Fukagawa, Masafumi ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Glargine; Insulin; Type 2 Diabetes Mellitus

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; ISOPHANE INSULIN;

AGED; ARTICLE; BLOOD GLUCOSE MONITORING; BOLUS INJECTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; JAPANESE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; WEIGHT GAIN; WEIGHT REDUCTION;

AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; JAPAN; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84864428321     PISSN: 03850005     EISSN: 21852243     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
2. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117.
3. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000; 23: 644-649.
4. Yokoyama H, Tada J, Kamikawa F, Kanno S, Yokota Y, Kuramitsu M. Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy. Diabetes Res Clin Pract 2006; 73: 35-40.
5. Riddle MC, Rosenstock J, Gerich J. Insulin Glargine 4002 Study Investigators: The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-3086.
6. Solnica B, Naskalski JW, Sieradzki J. Analytical performance of glucometers used for routine glucose self-monitoring of diabetic patients. Clin Chim Acta 2003; 331: 29-35.
7. Chen ET, Nichols JH, Duh SH, Hortin G. Performance evaluation of blood glucose monitoring devices. Diabetes Technol Ther 2003; 5: 749-768.
8. Seino Y, Nanjyo K, Tajima N, Kadowaki T, Kashiwagi A, Araki E, et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus: the committee of the Japan diabetes Society on the diagnostic criteria of diabetes mellitus. J Diabetes Investig 2010; 1: 212-228.
9. Binder C, Lauritzen T, Faber O, Pramming S. Insulin pharmacokinetics. Diabetes Care 1984; 7: 188-199.
10. Saloranta C, Hershon K, Ball M, Dickinson S, Holmes D. Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia. J Clin Endocrinol Metab 2002; 87: 4171-4176.
11. Takamura T, Sakurai M, Nakamura M, Shimizu A, Ota T, Misu H, et al. Factors associated with improvement of fasting plasma glucose level by mealtime dosing of a rapid-acting insulin analog in type 2 diabetes. Diabetes Res Clin Pract 2007; 75: 278-284.
12. Tanaka Y, Atsumi Y, Asahina T, Hosokawa K, Matsuoka K, Kinoshita J, et al. Usefulness of revised fasting plasma glucose criterion and characteristics of the insulin response to an oral glucose load in newly diagnosed Japanese diabetic subjects. Diabetes Care 1998; 21: 1133-1137.
13. Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edwards MB. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001; 24: 631-636.
14. Raskin P, Klaff L, Bergenstal R, Hallé JP, Donley D, Mecca T. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 2000; 23: 1666-1671.
15. Siegmund T, Weber S, Blankenfeld H, Oeffner A, Schumm-Draeger PM. Comparison of insulin glargine versus NPH insulin in people with Type 2 diabetes mellitus under outpatient-clinic conditions for 18 months using a basal-bolus regimen with a rapid-acting insulin analogue as mealtime insulin. Exp Clin Endocrinol Diabetes 2007; 115: 349-353.
16. Tamaki M, Shimizu T, Kanazawa A, Fujitani Y, Watada H, Kawamori R, et al. Effects of changes in basal/total daily insulin ratio in type 2 diabetes patients on intensive insulin therapy including insulin glargine (JUN-LAN Study 6). Diabetes Res Clin Pract 2008; 81: e1-e3.